CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
Fluoxetine Hydrochloride +1 moredrug
Likely dose
Fluoxetine Hydrochloride 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01247272
NCT01247272Phase 1Completed
CompareCT.gov

A Relative Bioavailability Study of 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions

Teva Pharmaceuticals USA·interventional·Posted Nov 24, 2010·Updated Feb 21, 2011

In Brief

A Phase 1 clinical trial evaluating Fluoxetine Hydrochloride and PROZAC WEEKLY® for Healthy. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This study compared the relative bioavailability (rate and extent of absorption) of 90 mg Fluoxetine Hydrochloride Capsules by Teva Pharmaceuticals, USA with that of 90 mg PROZAC WEEKLY® Capsules by Eli Lilly and Company following a single oral dose (1 x 90 mg) in healthy adult volunteers under fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 24, 2010
Enrollment StartMay 1, 2001
Primary CompletionJul 1, 2001
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.6 years ago

Interventions

Fluoxetine Hydrochloridedrug

90 mg Capsules

PROZAC WEEKLY®drug

90 mg Capsules